GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...

Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.

(Reuters) - U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age ...

Some groups of Alberta seniors will be able to get the RSV vaccine, for free, starting later this month.The Alberta ...

Pfizer (PFE) has reportedly succeeded in getting a U.K. court to invalidate two of GSK’s (GSK) patents for its RSV vaccine.

RSV hospitalizes thousands of people in the US every year. Three new vaccines could help stem the spread, but there are ...

Emma Walmsley, CEO of GSK, is nearly eight years into her effort to return the British pharma company to growth, and her work ...

Adults aged 60 and over with underlying co-morbidities are at high risk of developing severe infections from RSV Vaccine showed 82.6% overall vaccine efficacy against RSV-LRTD with 94.6% efficacy ...

NHL fans displeased with Wayne Gretzky's new commercial for AREXVY vaccine. (Image Source: Imagn). NHL fans have expressed their dissatisfaction on social media regarding Wayne Gretzky's latest ...

25, 2024 /PRNewswire/ -- GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that Arexvy (MAL24086007ARZ) has been approved in Malaysia for RSV, a common respiratory virus that can lead to ...